Beskrivelse
Krav
Fullmektig i Norge:
Org.nummer: 979993269
- Org.nummer:
- Foretaksnavn:
- Foretaksform:
- Næring:
-
Forretningsadresse:
Fullmektig i EP:
2015.06.29, US 201562186252 P
ANONYMOUS: "mTOR inhibitors", WIKIPEDIA, 24 January 2024 (2024-01-24), XP093123212, Retrieved from the Internet <URL:https://en.wikipedia.org/wiki/MTOR_inhibitors> [retrieved on 20240124] (B1)
CHARLOTTE BENSON ET AL: "A Retrospective Study of Patients with Malignant PEComa Receiving Treatment with Sirolimus or Temsirolimus: The Royal Marsden Hospital Experience", ANTICANCER RESEARCH, 1 January 2014 (2014-01-01), pages 3663 - 3668, XP055537945, Retrieved from the Internet <URL:http://ar.iiarjournals.org/content/34/7/3663.full.pdf> [retrieved on 20190102] (B1)
EL-HASHEMITE NISREEN ET AL: "Mutation inTSC2and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma", LANCET, vol. 361, no. 9366, 2003, pages 1348 - 1349, XP085425590, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(03)13044-9 (B1)
WO-A1-2008/109163 (B1)
MARK A. DICKSON ET AL: "Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: Clinical and molecular correlates", INTERNATIONAL JOURNAL OF CANCER, vol. 132, no. 7, 21 September 2012 (2012-09-21), US, pages 1711 - 1717, XP055537941, ISSN: 0020-7136, DOI: 10.1002/ijc.27800 (B1)
WAGNER A. ET AL: "ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial", JOURNAL OF CLINICAL ONCOLOGY, SUPPLEMENT 15 (37), 1 May 2019 (2019-05-01), pages 1 - 1, XP055904744, Retrieved from the Internet <URL:https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.11005> [retrieved on 20220323] (B1)
HENRY B ARMAH ET AL: "Malignant perivascular epithelioid cell tumor (PEComa) of the uterus with late renal and pulmonary metastases: a case report with review of the literature", DIAGNOSTIC PATHOLOGY, vol. 2, no. 1, 1 January 2007 (2007-01-01), Lo, pages 45, XP055537958, ISSN: 1746-1596, DOI: 10.1186/1746-1596-2-45 (B1)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Utgående
EP Registreringsbrev (3210) (PTEP3998069)
|
Innkommende, AR664077931
Søknadsskjema Patent
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Betalingshistorikk:
Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
---|---|---|---|---|
32501638 expand_more expand_less | 2025.02.19 | 7150 | BRYN AARFLOT AS | Betalt |
Valideringsgebyr EP-patent
7150 = 1 X 7150
|
||||
Årsavgift 10. avg. år (EP) expand_more expand_less | 2025.02.06 | 4160,0 | BRYN AARFLOT AS | Betalt og godkjent |
Årsavgift 10. avg. år (EP)
4160,0 = 1 X 4160,0
En ordre på saken er opprettet av: Ellen Pedersen (06.02.2025 09:15:01): Betalt |